DelveInsight, a leading market research and business consulting firm, has released its latest report, “Inflammatory Bowel Disease (IBD) Market Insights, Epidemiology, and Market Forecast – 2036.” The report delivers comprehensive insights into IBD epidemiology, current and emerging treatment paradigms, competitive intelligence, market trends, and forecast analysis across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Inflammatory Bowel Disease (IBD) Market

• The IBD market across the 7MM is expected to witness substantial growth through 2036, driven by increasing diagnosed prevalence, growing biologics adoption, and continuous therapeutic innovation.

• As per DelveInsight estimates, the current Inflammatory Bowel Disease market in the 7MM was valued at approximately USD 20 billion in 2025.

• The United States accounted for nearly 50% of the total diagnosed prevalent cases of IBD across the 7MM in 2025, representing the largest patient pool among all major markets.

• In 2025, the total diagnosed prevalent cases of IBD in the United States were estimated at approximately 2.8 million cases, with ulcerative colitis accounting for nearly 57% of total diagnosed cases.

• Moderate-to-severe disease cases represented the majority of IBD cases in the US, highlighting the growing need for advanced targeted therapies and biologic treatment options.

• Key IBD companies including AbbVie, Abivax, RedHill Biopharma, Takeda Pharmaceuticals, Janssen Pharmaceuticals, Eli Lilly, Merck, Gilead, and others are actively advancing innovative therapies for inflammatory bowel disease management.

• Promising emerging IBD therapies include Obefazimod (ABX464), RHB-204, Duvakitug, Tulisokibart (MK-7240), Guselkumab (TREMFYA), RVT-3101, Omilancor (BT-11), and others.

Gain strategic insights into the rapidly evolving Inflammatory Bowel Disease treatment landscape @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Inflammatory Bowel Disease Market

• Rising Prevalence of Crohn’s Disease and Ulcerative Colitis: The increasing global burden of inflammatory bowel disease, particularly among younger adults and aging populations, is significantly contributing to market expansion. Rising diagnosis rates and growing awareness regarding gastrointestinal disorders are further supporting treatment adoption.

• Growing Adoption of Advanced Biologics and Targeted Therapies: The IBD treatment paradigm is rapidly shifting toward advanced biologics, interleukin inhibitors, JAK inhibitors, S1P receptor modulators, and anti-integrin agents. Therapies such as SKYRIZI, RINVOQ, STELARA, ENTYVIO, and OMVOH are reshaping disease management strategies through improved efficacy and remission outcomes.

• Emergence of Precision Medicine and Biomarker-Driven Approaches: Increasing focus on systems biology, molecular characterization, and predictive biomarkers is enabling the development of personalized therapies tailored to specific patient subtypes, improving long-term treatment outcomes and reducing disease complications.

• Expanding Pipeline of Oral and Patient-Friendly Therapies: The emergence of oral small molecules and convenient administration platforms is expected to improve patient compliance and accessibility compared to traditional injectable biologics. Therapies such as Obefazimod and RHB-204 represent key innovations in patient-centric IBD care.

Inflammatory Bowel Disease Competitive Landscape

Several emerging therapies are expected to intensify competition within the IBD market over the coming years, including Obefazimod (ABX464), RHB-204, Duvakitug (TEV-574/SAR447189), Tulisokibart (MK-7240), RVT-3101, Omilancor (BT-11), and Guselkumab (TREMFYA).

These therapies target diverse inflammatory pathways including miR-124 modulation, cytokine suppression, anti-integrin signaling, JAK inhibition, microbiome-targeted approaches, and advanced immunomodulation mechanisms. The therapies are designed to improve clinical remission, reduce inflammation, enhance safety profiles, and address limitations associated with existing therapies.

Discover the next generation of therapies poised to capture significant IBD market share @ Emerging Inflammatory Bowel Disease Therapies

Recent Developments in the Inflammatory Bowel Disease Market

• In March 2026, AbbVie announced positive topline Phase III AFFIRM study results evaluating Risankizumab (SKYRIZI) subcutaneous induction therapy in Crohn’s disease patients.

• In January 2026, Abivax announced that topline Phase III maintenance results for Obefazimod (ABX464) in ulcerative colitis are expected in late Q2 2026, followed by a planned US regulatory filing later in the year.

• In February 2026, Sanofi and Teva reported that Duvakitug (TEV-574/SAR447189) demonstrated clinically meaningful and durable efficacy in Phase IIb maintenance studies across ulcerative colitis and Crohn’s disease.

• RedHill Biopharma continues to advance RHB-204, an investigational oral antibiotic combination therapy targeting MAP-positive Crohn’s disease patients, currently progressing through clinical development.

• Merck’s Tulisokibart (MK-7240) and Janssen’s Guselkumab (TREMFYA) are among the promising pipeline candidates expected to reshape the future IBD therapeutic landscape.

What is Inflammatory Bowel Disease (IBD)?

Inflammatory Bowel Disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract primarily comprising Crohn’s disease and ulcerative colitis. The condition results from immune system dysregulation triggered by genetic, microbial, environmental, and immunological factors.

IBD symptoms commonly include abdominal pain, diarrhea, rectal bleeding, fatigue, weight loss, bowel urgency, and nutritional deficiencies. The disease may also cause extra-intestinal manifestations affecting the skin, joints, liver, and eyes.

Current treatment strategies aim to reduce intestinal inflammation, achieve long-term remission, prevent complications, and improve quality of life through anti-inflammatory drugs, corticosteroids, biologics, immunomodulators, JAK inhibitors, and surgical interventions when necessary.

Inflammatory Bowel Disease Epidemiology Segmentation

The IBD epidemiology section provides insights into historical and forecasted patient trends across the 7MM from 2022–2036, segmented into:

• Total Diagnosed Prevalent Cases of IBD

• Type-specific Diagnosed Cases of IBD

• Severity-specific Diagnosed Cases of IBD

• Age-specific Diagnosed Cases of IBD

• Total Treated Cases of IBD

• Crohn’s Disease Cases

• Ulcerative Colitis Cases

Scope of the Inflammatory Bowel Disease Market Report

• Therapeutic Assessment: Current marketed and emerging IBD therapies

• IBD Market Dynamics: Key market drivers, barriers, and forecast assumptions

• Key Companies: AbbVie, Abivax, RedHill Biopharma, Takeda Pharmaceuticals, Janssen Pharmaceuticals, Merck, Eli Lilly, Gilead, and others

• Key Therapies: Obefazimod (ABX464), RHB-204, SKYRIZI, RINVOQ, ENTYVIO, STELARA, TREMFYA, Duvakitug, RVT-3101, OMVOH, and others

• Competitive Intelligence Analysis: SWOT analysis, market positioning, launch strategies, and conjoint analysis

• Market Access and Reimbursement Assessment across the 7MM

• KOL Insights, Analyst Views, and Unmet Needs Assessment

Explore comprehensive insights into Inflammatory Bowel Disease clinical development, epidemiology trends, and commercial opportunities @ Inflammatory Bowel Disease Clinical Trials and Market Outlook

Table of Contents

1. Inflammatory Bowel Disease Market Report Introduction

2. Executive Summary of IBD

3. Key Events and Transactions

4. Epidemiology and Market Methodology

5. IBD Market Overview at a Glance

6. Disease Background and Overview

7. Signs and Symptoms of IBD

8. Causes and Risk Factors

9. Diagnostic and Treatment Algorithms

10. Current Treatment Landscape

11. Emerging Therapies Analysis

12. Epidemiology and Patient Population

13. Market Size and Forecast Analysis

14. Market Share Distribution by Drug Class

15. Conjoint Analysis

16. SWOT Analysis

17. KOL Views

18. Market Access and Reimbursement

19. Market Drivers and Barriers

20. Appendix

21. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

For detailed competitive intelligence and future market opportunity assessment in Inflammatory Bowel Disease, visit https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end market intelligence and strategic business solutions to improve business performance. Get hassle-free access to healthcare and pharma market research reports through DelveInsight’s subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/